A Randomized, Open-Label, Phase 3 Study of Abemaciclib combined with Standard Adjuvant Endocrine Therapy versus Standard Endocrine Therapy Alone in Patients with High Risk Node Positive Early Stage Hormone Receptor Positive, Human Epidermal Receptor 2 Negative Breast Cancer
2022-06-29
عنوان الدراسة
A Randomized, Open-Label, Phase 3 Study of Abemaciclib combined with Standard Adjuvant Endocrine Therapy versus Standard Endocrine Therapy Alone in Patients with High Risk Node Positive Early Stage Hormone Receptor Positive, Human Epidermal Receptor 2 Negative Breast Cancer
داعم الدراسة
Eli Lilly
دواء الدراسة
abemaciclib
رقم بروتوكول الدراسة
I3Y-MC-JPCF
حالة الدراسة
Ongoing
موقع الدراسة
KFMC
مرحلة الدراسة
3
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.